arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Outlook Therapeutics, Inc.

OTLK

$1.02 ▲ +0.05 (+5.29%) at close

12 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Bullish

auto_awesome

Analytical Summary

Outlook Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $35.5M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC 203.3% ↗

FCF / Share $-1.49 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.41M

↓ -82.6% —

Net Income Profit after all expenses

$-62.42M

↑ +17.2% —

FCF / Share Free cash flow per share

$-1.49

↑ +59.8% —

Long-Term Debt Long-term obligations

$1.08M

↑ +552.5% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns ↑

100

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2014 10-K ↗
Revenue Growth YoY (%)	—	—	—	—	—	—	163.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1948%)	-19.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-337%)	27.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+249%)	-42.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-636%)	—	—
EPS Growth YoY (%)	55.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	15.4% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	22.6% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	11.4% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	47.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	26.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	17.2% Good ↑ Good Improving Year-over-year change in net income	-27.8% Weak ↓ Weak Declining Year-over-year change in net income	10.7% Fair ↑ Fair Improving Year-over-year change in net income	-24.2% Weak ↓ Weak Declining Year-over-year change in net income	-50.9% Weak ↓ Weak Declining Year-over-year change in net income	-2.1% Weak ↓ Weak Declining Year-over-year change in net income	-14.7% Weak ↓ Weak Declining Year-over-year change in net income	22.5% Good ↑ Good Improving Year-over-year change in net income	27.2% Excellent Excellent Year-over-year change in net income	-12.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	59.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-8.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	35.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	24.8% Good Good Year-over-year change in free cash flow	18.9% Good Good Year-over-year change in free cash flow	—	—	-38.1% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	—	—	—	—	—	—	39.8% Excellent Excellent Compound annual revenue growth over 3 years	-16.1% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2014 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	-445.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3071%)	—	—	—	—	—
Effective Tax Rate (%) (%)	2.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	8.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	9.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	10.8% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	—	—	—	-423.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3632%)	—	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	—	—	-401.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-414.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.19x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2014 10-K ↗
Return on Invested Capital (%)	203.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	98.1% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	368.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-721.9% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-1122.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-1192.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	219.5% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	104.2% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	108.5% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	2236.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	90.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-360.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-248.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-164.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-221.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-226.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-186.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-211.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-133.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-173.1% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-218.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-133.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	193.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1193%)	103.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+588%)	—	—	—	—	214.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1327%)	117.8% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+685%)	115.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+670%)	—	87.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+483%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2014 10-K ↗
Debt to Equity (x)	—	—	—	—	—	—	-0.07x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-111%)	-0.01x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-101%)	-0.00x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-101%)	-0.55x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-192%)	-0.05x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-109%)	—
Interest Coverage (x)	-236.86x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-150.95x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-45.80x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-40.52x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1118.68x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-40.31x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-10.47x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-7.62x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-6.38x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-35.26x Weak Weak Operating income divided by interest expense Optimal: > 5x	-20.27x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-8.08M	$-14.93M	$-23.39M	$-17.40M	$-14.48M	$-12.54M	$-6.94M	$-1.55M	$-3.03M	$529.59K	$-6.15M	$-2.35M
Debt / EBITDA (x)	—	—	—	—	—	—	-0.03x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.01x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.06x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.07x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2014 10-K ↗
Revenue per Share (USD)	$0.04	—	—	—	—	—	—	$12.52	$25.39	—	—	—
Basic EPS, GAAP (USD)	$-1.79	$-4.06	$-4.80	$-6.20	$-7.00	$-13.40	—	$-195.20	$-267.20	—	—	—
Free Cash Flow per Share (USD)	$-1.49	$-3.71	$-3.44	$-5.34	$-7.11	$-8.76	—	$-145.25	$-105.22	—	—	—
Book Value per Share (USD)	$-0.60	$-3.06	$-1.11	$0.77	$0.52	$0.44	$-11.28	$-56.59	$-215.94	$-36.49	$-919.33	—
Tangible Book Value per Share (USD)	$-0.60	$-3.06	$-1.11	$0.77	$0.52	$0.44	$-11.28	$-56.59	$-215.94	$-36.49	$-919.33	—
Basic Weighted Avg Shares (shares)	34.80M	18.55M	12.51M	10.60M	7.63M	3.63M	—	246,610	150,140	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2014 10-K ↗
Working Capital (USD)	$-28.43M	$-15.14M	$-15.75M	$7.79M	$14.76M	$2.06M	$-6.79M	$-28.74M	$-24.83M	$-14.76M	$-21.88M	—
LT Debt (USD)	—	—	—	—	—	—	$1.08M	$164.97K	$151.11K	$2.88M	$2.92M	—
Total Equity (USD)	$-32.19M	$-73.08M	$-14.44M	$8.74M	$4.61M	$2.83M	$-16.13M	$-25.54M	$-33.65M	$-5.20M	$-54.22M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2014 10-K ↗
Sales/Revenue/Turnover (USD)	$1.41M	—	—	—	—	—	$8.15M	$3.09M	$3.81M	$2.98M	$5.22M	—
Depreciation Expense (USD)	—	—	—	$163.62K	$163.62K	$219.42K	$3.36M	$3.05M	$2.69M	$2.39M	$1.82M	—
Net Income, GAAP (USD)	$-62.42M	$-75.37M	$-58.98M	$-66.05M	$-53.16M	$-35.24M	$-34.52M	$-30.09M	$-38.85M	$-53.33M	$-47.39M	—
Operating Cash Flow (USD)	$-51.83M	$-68.79M	$-42.97M	$-56.67M	$-54.25M	$-31.79M	$-32.29M	$-33.04M	$-15.51M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 46 quarters

Outlook Therapeutics, Inc.

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare OTLK with peers